Substituted phenyl groups improve the pharmacokinetic profile and anti-inflammatory effect of urea-based soluble epoxide hydrolase inhibitors in murine models

European Journal of Pharmaceutical Sciences

Volumn 48, Issue 4-5, 2013, Pages 619-627

  Liu, Jun Yan ^a   Lin, Yan Ping ^a   Qiu, Hong ^b   Morisseau, Christophe ^a   Rose, Tristan E ^a   Hwang, Sung Hee ^a   Chiamvimonvat, Nipavan ^b,c   Hammock, Bruce D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anti inflammation; Bioavailability; Eicosanoids; Metabolic profiling; Pharmacokinetics

Indexed keywords

1 (1 ACETYLPIPERIDIN 4 YL) 3 ADAMANTANYLUREA; 1 (1 METHANESULFONYLPIPERIDIN 4YL) 3 (4 TRIFLUOROMETHOXYPHENYL)UREA; 1 (4 TRIFLUOROMETHOXYPHENYL) 3 (1 CYCLOPROPANECARBOXYLPIPERIDIN 4 YL)UREA; 1 (4 TRIFLUOROMETHOXYPHENYL) 3 [(1YL UREIDO)CYCLOHEXYLOXY]BENZOIC ACID; 1 CHLOROPHENYL 3 (1 PROPIONYLPIPERIDIN 4 YL)UREA; 1 TRIFLUOROMETHOXYPHENYL 3 (1 PROPIONYLPIPERIDIN 4 YL)UREA; 4 [4 [3 (1 ADAMANTYL)UREIDO]CYCLOHEXYLOXY]BENZOIC ACID; ANTIINFLAMMATORY AGENT; EPOXIDE; GAMMA INTERFERON; HYDROLASE INHIBITOR; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; OXYLIPIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STABILITY; FATTY ACID BLOOD LEVEL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; EPOXIDE HYDROLASES; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MICE; UREA;

EID: 84873462464     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2012.12.013     Document Type: Article

References (40)

1. D. Ai, W. Pang, N. Li, M. Xu, P.D. Jones, J. Yang, Y. Zhang, N. Chiamvimonvat, J.Y.J. Shyy, B.D. Hammock, and Y. Zhu Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy Proc. Natl. Acad Sci. USA 106 2009 564 569
2. B. Borhan, A.D. Jones, F. Pinot, D.F. Grant, M.J. Kurth, and B.D. Hammock Mechanism of soluble epoxide hydrolase-formation of an alpha-hydroxy ester-enzyme intermediate through Asp-333 J. Biol. Chem. 270 1995 26923 26930
3. N. Chacos, J. Capdevila, J.R. Falck, S. Manna, C. Martin-Wixtrom, S.S. Gill, B.D. Hammock, and R.W. Estabrook The reaction of arachidonic acid epoxides (epoxyeicosatrienoic acids) with a cytosolic epoxide hydrolase Arch. Biochem. Biophys. 223 1983 639 648
4. K.R. Chaudhary, M. Abukhashim, S.H. Hwang, B.D. Hammock, and J.M. Seubert Inhibition of soluble epoxide hydrolase by trans-4-[4-(3-adamantan-1-yl-ureido) -cyclohexyloxy]-benzoic acid is protective against ischemia-reperfusion injury J. Cardiovasc. Pharm. 55 2010 67 73
5. B.B. Davis, D.A. Thompson, L.L. Howard, C. Morisseau, B.D. Hammock, and R.H. Weiss Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation Proc. Natl. Acad Sci. USA 99 2002 2222 2227
6. A.M. Dorrance, N. Rupp, D.M. Pollock, J.W. Newman, B.D. Hammock, and J.D. Imig An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats J. Cardiovasc. Pharm. 46 2005 842 848
7. R. Faggioni, J. Fuller, A. Moser, K.R. Feingold, and C. Grunfeld LPS-induced anorexia in leptin-deficient (ob/ob) and leptin receptor-deficient (db/db) mice Am. J. Physiol.-Reg. I 42 1997 R181 R186
8. B.D. Hammock, M. Ratcliff, and D.A. Schooley Hydration of an 18O epoxide by a cytosolic epoxide hydrolase from mouse liver Life Sci. 27 1980 1635 1641
9. H. Huang, C. Morisseau, J.F. Wang, T.X. Yang, J.R. Falck, B.D. Hammock, and M.H. Wang Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats Am. J. Physiol.-Renal. 293 2007 F342 F349
10. S.H. Hwang, H.J. Tsai, J.Y. Liu, C. Morisseau, and B.D. Hammock Orally bioavailable potent soluble epoxide hydrolase inhibitors J. Med. Chem. 50 2007 3825 3840
11. J.D. Imig, X.Y. Zhao, J.H. Capdevila, C. Morisseau, and B.D. Hammock Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension Hypertension 39 2002 690 694
12. J.D. Imig, X.Y. Zhao, C.Z. Zaharis, J.J. Olearczyk, D.M. Pollock, J.W. Newman, I.H. Kim, T. Watanabe, and B.D. Hammock An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension Hypertension 46 2005 975 981
13. B. Inceoglu, S.L. Jinks, K.R. Schmelzer, T. Waite, I.H. Kim, and B.D. Hammock Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain Life Sci. 79 2006 2311 2319
14. R.H. Ingraham, R.D. Gless, and H.Y. Lo Soluble epoxide hydrolase inhibitors and their potential for treatment of multiple pathologic conditions Curr. Med. Chem. 18 2011 587 603
15. P.M. Johnson, S.K. Vogt, M.W. Burney, and L.J. Muglia COX-2 inhibition attenuates anorexia during systemic inflammation without impairing cytokine production Am. J. Physiol.-Endoc. M 282 2002 E650 E656
16. P.D. Jones, H.J. Tsai, Z.N. Do, C. Morisseau, and B.D. Hammock Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase Bioorg. Med. Chem. Lett. 16 2006 5212 5216
17. P.D. Jones, N.M. Wolf, C. Morisseau, P. Whetstone, B. Hock, and B.D. Hammock Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies Anal. Biochem. 343 2005 66 75
18. I.H. Kim, C. Morisseau, T. Watanabe, and B.D. Hammock Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility J. Med. Chem. 47 2004 2110 2122
19. G. Lamoureux, and G. Artavia Use of the adamantane structure in medicinal chemistry Curr. Med. Chem. 17 2010 2967 2978
20. N. Li, J.Y. Liu, V. Timofeyev, H. Qiu, S.H. Hwang, D. Tuteja, L. Lu, J. Yang, H. Mochida, R. Low, B.D. Hammock, and N. Chiamvimonvat Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: insight gained using metabolomic approaches J. Mol. Cell. Cardiol. 47 2009 835 845
21. J.Y. Liu, H.J. Tsai, S.H. Hwang, P.D. Jones, C. Morisseau, and B.D. Hammock Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation Brit. J. Pharmacol. 156 2009 284 296
22. D. Loch, A. Hoey, C. Morisseau, B.O. Hammock, and L. Brown Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase Cell Biochem. Biophys. 47 2007 87 97
23. M. Manhiani, J.E. Quigley, S.F. Knight, S. Tasoobshirazi, T. Moore, M.W. Brands, B.D. Hammock, and J.D. Imig Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension Am. J. Physiol.-Renal. 297 2009 F740 F748
24. C. Morisseau, M.H. Goodrow, D. Dowdy, J. Zheng, J.F. Greene, J.R. Sanborn, and B.D. Hammock Potent urea and carbamate inhibitors of soluble epoxide hydrolases Proc. Natl. Acad Sci. USA 96 1999 8849 8854
25. C. Morisseau, M.H. Goodrow, J.W. Newman, C.E. Wheelock, D.L. Dowdy, and B.D. Hammock Structural refinement of inhibitors of urea-based soluble epoxide hydrolases Biochem. Pharmacol. 63 2002 1599 1608
26. C. Morisseau, and B.D. Hammock Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles Annu. Rev. Pharmacol. Toxicol. 45 2005 311 333
27. J.W. Newman, C. Morisseau, and B.D. Hammock Epoxide hydrolases: their roles and interactions with lipid metabolism Prog. Lipid Res. 44 2005 1 51
28. A.R. Parrish, G. Chen, R.C. Burghardt, T. Watanabe, C. Morisseau, and B.D. Hammock Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolase Cell Biol. Toxicol. 25 2009 217 225
29. C.R. PlataSalaman Anorexia during acute and chronic disease Nutrition 12 1996 69 78
30. H. Qiu, N. Li, J.Y. Liu, T.R. Harris, B.D. Hammock, and N. Chiamvimonvat Soluble epoxide hydrolase inhibitors and heart failure Cardiovasc. Ther. 29 2011 99 111
31. M. Revermann, E. Barbosa-Sicard, E. Dony, R.T. Schermuly, C. Morisseau, G. Geisslinger, I. Fleming, B.D. Hammock, and R.P. Brandes Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats J. Hypertens. 27 2009 322 331
32. T.E. Rose, C. Morisseau, J.Y. Liu, B. Inceoglu, P.D. Jones, J.R. Sanborn, and B.D. Hammock 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain J. Med. Chem. 53 2010 7067 7075
33. K.R. Schmelzer, B. Inceoglu, L. Kubala, I.H. Kim, S.L. Jinks, J.P. Eiserich, and B.D. Hammock Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors Proc. Natl. Acad Sci. USA 103 2006 13646 13651
34. K.R. Schmelzer, L. Kubala, J.W. Newman, I.H. Kim, J.P. Eiserich, and B.D. Hammock Soluble epoxide hydrolase is a therapeutic target for acute inflammation Proc. Natl. Acad Sci. USA 102 2005 9772 9777
35. K.R. Smith, K.E. Pinkerton, T. Watanabe, T.L. Pedersen, S.J. Ma, and B.D. Hammock Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor Proc. Natl. Acad Sci. USA 102 2005 2186 2191
36. H.J. Tsai, S.H. Hwang, C. Morisseau, J. Yang, P.D. Jones, T. Kasagami, I.H. Kim, and B.D. Hammock Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs Eur. J. Pharm. Sci. 40 2010 222 238
37. D. Xu, N. Li, Y. He, V. Timofeyev, L. Lu, H.J. Tsai, I.H. Kim, D. Tuteja, R.K.P. Mateo, A. Singapuri, B.B. Davis, R. Low, B.D. Hammock, and N. Chiamvimonvat Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors Proc. Natl. Acad Sci. USA 103 2006 18733 18738
38. J. Yang, K. Schmelzer, K. Georgi, and B.D. Hammock Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry Anal. Chem. 81 2009 8085 8093
39. Z.G. Yu, F.Y. Xu, L.M. Huse, C. Morisseau, A.J. Draper, J.W. Newman, C. Parker, L. Graham, M.M. Engler, B.D. Hammock, D.C. Zeldin, and D.L. Kroetz Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids Circ. Res. 87 2000 992 998
40. X.Y. Zhao, T. Yamamoto, J.W. Newman, I.H. Kim, T. Watanabe, B.D. Hammock, J. Stewart, J.S. Pollock, D.M. Pollock, and J.D. Imig Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage J. Am. Soc. Nephrol. 15 2004 1244 1253